MDQ (Mood Disorder Questionnaire): Bipolar Disorder Screening Tool — Purpose, Scoring, and Clinical Use

The Mood Disorder Questionnaire (MDQ) is a brief, self-report screening instrument designed to identify individuals who may have bipolar spectrum disorders — primarily bipolar I disorder and bipolar II disorder. Developed by Robert M.A. Hirschfeld and colleagues and published in the American Journal of Psychiatry in 2000, the MDQ was one of the first validated screening tools specifically targeting bipolar disorder in clinical and community settings.

The MDQ was created to address a well-documented problem in psychiatric practice: bipolar disorder is frequently misdiagnosed as major depressive disorder. Research consistently shows that individuals with bipolar disorder wait an average of 5 to 10 years from symptom onset to receive an accurate diagnosis. Because most people with bipolar disorder seek treatment during depressive episodes rather than manic or hypomanic episodes, clinicians may not identify the full clinical picture without specifically screening for a history of mania or hypomania.

The MDQ is not a diagnostic instrument. It is a screening tool — meaning its purpose is to flag individuals who warrant further clinical evaluation for bipolar disorder. A positive screen on the MDQ does not confirm a diagnosis, and a negative screen does not rule one out. Its value lies in prompting clinicians to conduct a more thorough diagnostic assessment when bipolar features might otherwise be overlooked.

The MDQ measures the lifetime occurrence of manic or hypomanic symptoms as defined by DSM criteria for bipolar disorder. It is structured around three core components:

• Part 1 — Symptom Checklist (13 yes/no items): These items correspond to the DSM criteria for a manic or hypomanic episode. They ask whether the respondent has ever experienced specific symptoms, including elevated or irritable mood, grandiosity, decreased need for sleep, rapid or pressured speech, racing thoughts, increased goal-directed activity, distractibility, excessive involvement in pleasurable activities with potential for painful consequences, and increased energy. The items are worded in accessible, everyday language to make them understandable to individuals without clinical training.
• Part 2 — Co-occurrence: A single question asks whether several of these symptoms occurred during the same period of time. This is a critical component because the DSM-5-TR requires that manic or hypomanic symptoms cluster together within a distinct episode, rather than occurring in isolation across different contexts or time periods.
• Part 3 — Functional Impairment: A single question asks how much the symptoms caused problems in the person's life — rated as "no problem," "minor problem," "moderate problem," or "serious problem." This item captures the functional impairment criterion that distinguishes clinically significant episodes from normal variations in mood or temperament.

Together, these three components mirror the essential diagnostic logic of the DSM-5-TR: the presence of characteristic symptoms, their co-occurrence within a discrete episode, and their impact on functioning or well-being.

The MDQ was originally developed and validated for use with adult psychiatric outpatients — specifically individuals presenting for treatment of mood-related complaints. It has since been studied in a variety of populations, including primary care patients, community samples, and individuals in inpatient psychiatric settings.

The target population is adults (18 years and older) who may be experiencing mood symptoms and for whom a bipolar spectrum diagnosis has not yet been established or considered. The MDQ is particularly useful in the following clinical scenarios:

• Patients presenting with depression: Because depressive episodes are the most common reason individuals with bipolar disorder seek care, the MDQ can prompt clinicians to evaluate for a history of mania or hypomania that the patient may not spontaneously report.
• Patients with treatment-resistant depression: Failure to respond to standard antidepressant treatment is sometimes associated with an unrecognized bipolar diagnosis. Screening with the MDQ can help identify whether bipolar disorder should be considered.
• Primary care settings: Where mood disorders are commonly managed but comprehensive psychiatric evaluations may not be feasible, the MDQ provides a quick, structured first step.
• Research settings: The MDQ is widely used in epidemiological and clinical research to estimate the prevalence of bipolar spectrum disorders and to identify potential research participants.

The MDQ is not validated for children or adolescents. Screening for pediatric bipolar disorder requires different instruments and careful clinical evaluation due to the developmental complexity of mood presentation in younger populations.

The MDQ is a paper-and-pencil self-report questionnaire that takes approximately 5 minutes to complete. It can be administered in a waiting room before a clinical appointment, handed to a patient during a session, or completed as part of an intake assessment battery. Digital versions are also available for electronic health record integration and online administration.

The questionnaire is written at approximately a sixth- to eighth-grade reading level, making it accessible to most adult populations. It requires no special training for the respondent to complete, although clinicians interpreting the results should understand the scoring conventions and the tool's psychometric properties.

The MDQ can be administered by any healthcare professional — including psychiatrists, psychologists, primary care physicians, nurse practitioners, social workers, and clinical intake coordinators. It does not require a licensed mental health professional to administer, though interpretation should always occur within a clinical context.

Importantly, the MDQ asks about lifetime symptom history, not current symptoms. This means a person could screen positive even if they are not currently experiencing manic or hypomanic symptoms, which is appropriate given that bipolar disorder is an episodic condition with long intervals between mood episodes in many individuals.

The standard scoring algorithm for the MDQ uses a three-gate approach — all three components must meet threshold to constitute a positive screen:

• Gate 1: The respondent endorses 7 or more of the 13 symptom items in Part 1.
• Gate 2: The respondent answers "yes" to the co-occurrence question in Part 2 — confirming that several symptoms happened during the same time period.
• Gate 3: The respondent rates the functional impact as "moderate" or "serious" in Part 3.

A screen is considered positive only when all three gates are met simultaneously. If any gate is not met, the screen is considered negative.

Interpreting a Positive Screen: A positive MDQ result indicates that the individual's self-reported symptom history is consistent with patterns seen in bipolar disorder and that further diagnostic evaluation is warranted. It does not mean the person has bipolar disorder. Many conditions can produce overlapping symptoms — including ADHD, borderline personality disorder, substance use disorders, and certain medical conditions — and the MDQ cannot differentiate among them.

Interpreting a Negative Screen: A negative MDQ result means the person did not meet the screening threshold. However, given the tool's sensitivity limitations (discussed below), a negative result does not definitively rule out bipolar disorder. Individuals with bipolar II disorder or subsyndromal hypomanic episodes may not endorse enough symptoms to trigger a positive screen, particularly if they lack insight into their hypomanic episodes or perceive them as normal functioning.

Some researchers have proposed alternative scoring thresholds — such as lowering the symptom count to 5 or more, or modifying the functional impairment gate — to improve sensitivity in certain populations. These modified thresholds may increase the detection of bipolar II disorder at the cost of reduced specificity (more false positives).

The psychometric properties of the MDQ have been evaluated in multiple studies across diverse populations, with results that vary meaningfully depending on the clinical setting:

Psychiatric outpatient settings (original validation): In Hirschfeld et al.'s original 2000 study of 198 psychiatric outpatients, the MDQ demonstrated a sensitivity of 0.73 and a specificity of 0.90 using the standard scoring algorithm. This means the tool correctly identified 73% of individuals who had a clinician-confirmed bipolar diagnosis and correctly classified 90% of individuals without bipolar disorder. The overall diagnostic accuracy was considered good for a brief screening instrument.

General population and primary care settings: When applied to community or primary care samples — where the base rate of bipolar disorder is lower — the MDQ's performance has been less robust. Studies in general population samples have reported sensitivity ranging from 0.28 to 0.58, meaning the tool misses a substantial proportion of bipolar cases in these lower-prevalence settings. Specificity remains relatively high (0.85–0.97), so false positives are less common, but the high miss rate is a significant limitation.

Bipolar II detection: The MDQ is notably less effective at identifying bipolar II disorder compared to bipolar I disorder. Because hypomanic episodes are shorter, less severe, and often experienced as ego-syntonic (meaning the person may feel good during them and not recognize them as abnormal), individuals with bipolar II disorder frequently do not endorse enough symptoms on the MDQ to screen positive.

Reliability: The MDQ has demonstrated acceptable internal consistency, with Cronbach's alpha values typically reported between 0.84 and 0.90 for the 13-item symptom checklist. Test-retest reliability has been less extensively studied but is generally reported as adequate in studies that have assessed it.

A 2019 meta-analysis published in Acta Psychiatrica Scandinavica synthesized data across multiple validation studies and confirmed that the MDQ performs best in psychiatric settings where the pre-test probability of bipolar disorder is higher. In low-prevalence populations, the positive predictive value drops substantially, which limits its utility as a standalone community screening tool.

Despite its widespread use and practical utility, the MDQ has several important limitations that clinicians and individuals completing the tool should understand:

• Limited sensitivity for bipolar II disorder: As noted above, the MDQ was originally validated in a sample with a high proportion of bipolar I cases. Its ability to detect bipolar II disorder — which is at least as prevalent and clinically significant — is substantially lower. This is arguably the tool's most important limitation, as bipolar II disorder is precisely the diagnosis most commonly missed in clinical practice.
• Self-report bias: The MDQ relies entirely on the respondent's memory, insight, and willingness to report symptoms. Individuals may underreport hypomanic symptoms they experienced positively (increased energy, productivity, confidence) or overreport symptoms due to current mood state. Depressed individuals may have difficulty recalling past hypomanic states with accuracy.
• No differential diagnosis: The MDQ cannot distinguish bipolar disorder from other conditions that share symptomatic overlap. ADHD, borderline personality disorder, cyclothymic disorder, substance-induced mood episodes, and certain medical conditions (such as hyperthyroidism) can all produce symptoms that might lead to a positive MDQ screen.
• Cultural and linguistic considerations: While the MDQ has been translated into multiple languages and validated in several countries, cross-cultural differences in the expression and reporting of mood symptoms may affect its performance. Norms established in one population may not generalize directly to others.
• Binary outcome: The MDQ produces a positive or negative screening result — it does not provide a dimensional score indicating severity or a probability estimate. This all-or-nothing approach may miss individuals who fall just below the threshold but still warrant clinical attention.
• Lifetime retrospective assessment: Asking about symptoms that may have occurred years or decades ago introduces recall bias. Individuals may conflate normal mood fluctuations with clinically significant episodes, or On the other hand, may forget or minimize past episodes.

These limitations underscore that the MDQ should always be used as one component of a comprehensive clinical evaluation — never as the sole basis for diagnostic or treatment decisions.

In clinical practice, the MDQ serves as a first-step screening tool that informs — but does not replace — a thorough diagnostic assessment. Here is how results are typically integrated into clinical care:

Positive screen: When a patient screens positive on the MDQ, the clinician proceeds with a comprehensive diagnostic interview. This typically includes a detailed mood history, assessment of the duration, frequency, and severity of mood episodes, a review of DSM-5-TR criteria for bipolar I disorder, bipolar II disorder, and cyclothymic disorder, collateral information from family members when possible, and evaluation of alternative explanations for the symptoms endorsed. Structured diagnostic interviews such as the Structured Clinical Interview for DSM-5 (SCID-5) or the Mini International Neuropsychiatric Interview (MINI) are often used to confirm or rule out a bipolar diagnosis following a positive MDQ screen.

Negative screen: A negative screen generally reduces the clinician's index of suspicion for bipolar disorder but does not eliminate it. If clinical history, family history, treatment response, or other factors still suggest a bipolar spectrum condition, the clinician should pursue further evaluation regardless of the MDQ result.

Treatment planning: The MDQ does not directly guide treatment selection. However, by facilitating the early and accurate identification of bipolar disorder, it can prevent the inadvertent prescription of antidepressant monotherapy — which is generally not recommended as first-line treatment for bipolar depression and may trigger manic switches in some individuals.

Longitudinal monitoring: Because the MDQ assesses lifetime symptoms, it is not ideal for tracking symptom changes over time. Clinicians who need to monitor mood episodes prospectively typically use other instruments, such as mood charts, the Young Mania Rating Scale (YMRS) for manic symptoms, or the Patient Health Questionnaire (PHQ-9) for depressive symptoms.

The MDQ is a publicly available instrument that can be accessed through several channels:

• Published literature: The full questionnaire was published in the original 2000 American Journal of Psychiatry article by Hirschfeld et al. and has been reproduced in numerous clinical textbooks and screening manuals.
• Professional organizations: The Depression and Bipolar Support Alliance (DBSA) has historically made the MDQ available on its website for educational purposes.
• Clinical settings: Many psychiatric practices, primary care offices, and mental health clinics include the MDQ in their standard intake assessment batteries.
• Electronic health records: Some EHR platforms include the MDQ as a built-in screening measure that can be administered digitally during patient intake.

The MDQ is available in English and has been translated and validated in multiple languages, including Spanish, Portuguese, Chinese, Korean, Turkish, and Arabic, among others. When using translated versions, clinicians should verify that the specific translation has been validated in the relevant cultural population.

Important note: While the MDQ is freely available and can be completed without professional supervision, interpretation of results should always occur within a clinical context. Individuals who complete the MDQ on their own and obtain a result consistent with a positive screen should bring this information to a qualified mental health professional for proper evaluation — not use it to self-diagnose.

If you are experiencing significant mood disturbances — whether episodes of depression, periods of unusually elevated or irritable mood, or cycles between the two — seeking professional evaluation is strongly recommended, regardless of what any screening tool indicates. Consider reaching out to a mental health professional if you experience:

• Periods of markedly elevated mood, energy, or activity that feel distinctly different from your baseline
• Decreased need for sleep without feeling tired
• Depressive episodes that have not responded adequately to standard antidepressant treatment
• Impulsive behaviors during mood episodes — excessive spending, risky sexual behavior, or grandiose plans — that are out of character
• A family history of bipolar disorder combined with personal mood symptoms
• Rapid shifts between depression and elevated mood
• Functional impairment at work, in relationships, or in daily life related to mood instability

A screening tool like the MDQ can be a useful starting point for a conversation with a clinician, but it is no substitute for a comprehensive diagnostic evaluation. Bipolar disorder is a treatable condition, and accurate diagnosis is the critical first step toward effective management.

If you or someone you know is in crisis, contact the 988 Suicide & Crisis Lifeline (call or text 988), the Crisis Text Line (text HOME to 741741), or go to the nearest emergency room.